摘要
目的探索莫西沙星对多重耐药肺结核(MDR-TB)患者血清降钙素原(PCT)和可溶性骨髓系细胞触发受体-1(sTREM-1)水平的影响。方法综合分析180例MDR-TB患者,随机等分为莫西沙星组和对照组,动态观察治疗后2个月和6个月血清PCT和sTREM-1水平改变,以及临床治愈情况。同时分析莫西沙星治疗后PCT和sTREM-1水平改变的相关性。结果治疗后6个月莫西沙星组累计显效率(85.6%)明显高于对照组(70.0%),差异有统计学意义(P<0.05)。经治疗后,莫西沙星组患者血清sTREM-1和PCT水平明显下降,血清sTREM-1在治疗后2个月和6个月的水平明显低于对照组患者,差异有统计学意义(P<0.05)。结论莫西沙星可以有效控制MRD-TB患者病情程度,并降低血清PCT和sTREM-1的水平。
Objective To evaluate the influence of moxifloxacin on serum levels of procalcitonin（PCT）and sTREM-1 in patients with multiple drug resistance tuberculosis（MDR-TB）.Methods One hundred and eighty patients with MDR-TB were enrolled in this study and randomly divided into two group：moxifloxacin group and control group.The levels of PCT and sTREM-1 were under dynamic observation in three time points（before the treatment,2 months and 6 months after treatment）.Correlation analysis was used to estimate the association between moxifloxasin and changes of PCT and sTREM-1.Results The accumulative curative effect rate of moxifloxacin group（85.6%）was significantly higher than that of the control group（70.0%）（P〈0.05）.The levels of PCT and sTREM-1 were significantly lower than before the treatment in moxifloxicin group.And the levels of PCT and sTREM-1 of 2 months and 6 months after the treatment were significantly lower than that in control group（P〈0.05）.Conclusion Moxifloxacin can effectively control the MDR-TB and decrease the serum levels of PCT and sTREM-1.
出处
《检验医学与临床》
CAS
2016年第22期3138-3140,共3页
Laboratory Medicine and Clinic
基金
四川省卫生厅资助项目(09461)
